News

Cohance Lifesciences shares need to cross this level to recover all the losses for 2026Cohance Lifesciences shares have advanced in four of the past seven sessions and is now attempting to recover its losses for 2026. The key level to watch is ₹528, which the stock had touched on December 31, 2025.By Meghna Sen  April 28, 2026, 11:38:44 AM IST (Updated)2 Min ReadShares of Cohance Lifesciences Ltd. surged for a second straight session on Tuesday, April 28, rising as much as 19% and extending Monday's 20% rally. The stock has gained 43% over the last two trading sessions.

It has advanced in four of the past seven sessions and is now attempting to recover its losses for 2026. The key level to watch is ₹528, which the stock had touched on December 31, 2025.

The sharp move comes after the company announced a leadership transition.

Leadership churn

Cohance Lifesciences said Umang Vohra will take over as Executive Chairman from May 1, 2026, and assume the role of Group Chief Executive Officer (CEO) from May 20, 2026.

Current Executive Chairman Vivek Sharma will step down for personal reasons but will remain associated with the company as an advisor for the next nine months to ensure a smooth transition.

Vohra had earlier stepped down as Group CEO of Cipla, completing his tenure in March 2026, with Achin Gupta named as his successor.

In his statement, Vohra said the company’s technology capabilities, strong research and development (R&D) base, and leadership team provide a solid foundation for future growth, adding that he looks forward to building long-term value for stakeholders.

Cohance Lifesciences Managing Director Dr V Prasada Raju exited in October last year. Chief Executive Officer Dr Sudhir Kumar Singh had also exited in July 2025. The company had announced a new structure with three business CEOs reporting to Executive Chairman Vivek Sharma.

Weak numbers

The company posted a weak financial performance. Net profit dropped 54% to ₹169 crore. Its 9M FY26 revenue declined 7% to ₹1,649 crore, margins fell to 20% from 32%.

The company's Nacharam facility has received a USFDA warning letter.

FY26 has been termed a transition year, with guidance revised to an early-to-mid double-digit decline. The timeline to achieve $1 billion revenue by 2030 may be pushed out.

The company operates across complex active pharmaceutical ingredients (APIs), antibody-drug conjugates (ADCs), oligonucleotides, as well as intermediates, performance materials and specialty ingredients.

Cohance Lifesciences said the appointment is a strategic move aimed at bringing in leadership aligned with its next phase of transformation and growth.

Cohance Lifesciences shares hit a 52-week high of ₹1,189 on April 29, 2025, and a 52-week low of ₹267.8 on March 9, 2026. The stock saw a peak-to-trough decline of around 77% and remains down 57% from its 52-week high.

Shares of the company were trading 15.51% higher at ₹499.10. Despite the recent rally, the stock is still down about 5% so far in 2026.Continue ReadingFirst Published: Apr 28, 2026 11:18 AM ISTTagscohanceshare market today